Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926941 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL5459892 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL9955207 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL30492127 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL6263078 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL7530714 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL707486 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL2904077 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL3948914 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL8882093 | 0.98 | ACE2 (0.43) | ACE2GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654665-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083906-A2 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) | 2012-06-28 | — | — | WO | disclosed |